PMC:7441777 / 3936-4273 JSONTXT

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T23","span":{"begin":30,"end":35},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T24","span":{"begin":192,"end":193},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T25","span":{"begin":256,"end":261},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"}],"text":"More importantly, there is no human polymerase counterpart that resembles the sequence/structural homology with RdRp from coronaviruses, and hence, the development of RdRp inhibitors could be a potential therapeutic strategy without risk of crosstalk with human polymerases (Borgio et al., 2020; Subissi et al., 2014; Zhai et al., 2005)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T41","span":{"begin":172,"end":182},"obj":"Chemical"}],"attributes":[{"id":"A41","pred":"chebi_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"More importantly, there is no human polymerase counterpart that resembles the sequence/structural homology with RdRp from coronaviruses, and hence, the development of RdRp inhibitors could be a potential therapeutic strategy without risk of crosstalk with human polymerases (Borgio et al., 2020; Subissi et al., 2014; Zhai et al., 2005)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"164","span":{"begin":112,"end":116},"obj":"Gene"},{"id":"165","span":{"begin":167,"end":171},"obj":"Gene"},{"id":"177","span":{"begin":30,"end":35},"obj":"Species"},{"id":"178","span":{"begin":122,"end":135},"obj":"Species"},{"id":"179","span":{"begin":256,"end":261},"obj":"Species"}],"attributes":[{"id":"A164","pred":"tao:has_database_id","subj":"164","obj":"Gene:43740578"},{"id":"A165","pred":"tao:has_database_id","subj":"165","obj":"Gene:43740578"},{"id":"A177","pred":"tao:has_database_id","subj":"177","obj":"Tax:9606"},{"id":"A178","pred":"tao:has_database_id","subj":"178","obj":"Tax:11118"},{"id":"A179","pred":"tao:has_database_id","subj":"179","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"More importantly, there is no human polymerase counterpart that resembles the sequence/structural homology with RdRp from coronaviruses, and hence, the development of RdRp inhibitors could be a potential therapeutic strategy without risk of crosstalk with human polymerases (Borgio et al., 2020; Subissi et al., 2014; Zhai et al., 2005)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T36","span":{"begin":0,"end":337},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"More importantly, there is no human polymerase counterpart that resembles the sequence/structural homology with RdRp from coronaviruses, and hence, the development of RdRp inhibitors could be a potential therapeutic strategy without risk of crosstalk with human polymerases (Borgio et al., 2020; Subissi et al., 2014; Zhai et al., 2005)."}

{"project":"2_test","denotations":[{"id":"32720577-32399096-56195091","span":{"begin":290,"end":294},"obj":"32399096"},{"id":"32720577-25197083-56195092","span":{"begin":312,"end":316},"obj":"25197083"}],"text":"More importantly, there is no human polymerase counterpart that resembles the sequence/structural homology with RdRp from coronaviruses, and hence, the development of RdRp inhibitors could be a potential therapeutic strategy without risk of crosstalk with human polymerases (Borgio et al., 2020; Subissi et al., 2014; Zhai et al., 2005)."}